UB Paderborn / Katalog / Suche / in CDI

Experimental demonstration of a receiver beating the standard quantum limit for multiple nonorthogonal state discrimination

Nature photonics, 2013-02, Vol.7 (2), p.147-152

2013

Volltextzugriff (PDF)

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

The New England journal of medicine, 2017-11, Vol.377 (19), p.1836-1846

2017

Volltextzugriff (PDF)

Demonstration of nonorthogonal multi-state discrimination below the standard quantum limit

2013 IEEE Photonics Society Summer Topical Meeting Series, 2013, p.166-166

2013

Volltextzugriff (PDF)

Beating the standard quantum limit for nonorthogonal multi-state discrimination

CLEO: 2013, 2013, p.1-2

2013

Volltextzugriff (PDF)

A Phase II Trial of Lutikizumab, an Anti–Interleukin‐1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis

Arthritis & rheumatology (Hoboken, N.J.), 2019-07, Vol.71 (7), p.1056-1069

2019

Volltextzugriff (PDF)

Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study

British journal of dermatology (1951), 2021-05, Vol.184 (5), p.857-870

2021

Volltextzugriff (PDF)

Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis

The New England journal of medicine, 2022-12, Vol.387 (25), p.2317-2330

2022

Volltextzugriff (PDF)

A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy

Journal of the European Academy of Dermatology and Venereology, 2021-02, Vol.35 (2), p.464-475

2021

Volltextzugriff (PDF)

A Dimensional Analysis of Caregiver Burden among Spouses and Adult Children

The Gerontologist, 2011-06, Vol.51 (3), p.321-331

2011

Volltextzugriff (PDF)

Safety, tolerability, and pharmacodynamics of an anti-interleukin-1α/β dual variable domain immunoglobulin in patients with osteoarthritis of the knee: a randomized phase 1 study

Osteoarthritis and cartilage, 2017-12, Vol.25 (12), p.1952-1961

2017

Volltextzugriff (PDF)

Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2022-09, Vol.400 (10356), p.908-919

2022

Volltextzugriff (PDF)

Selective VIP Receptor Agonists Facilitate Immune Transformation for Dopaminergic Neuroprotection in MPTP-Intoxicated Mice

The Journal of neuroscience, 2015-12, Vol.35 (50), p.16463-16478

2015

Volltextzugriff (PDF)

Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir

The Journal of pharmacology and experimental therapeutics, 2019-08, Vol.370 (2), p.278

2019

Volltextzugriff (PDF)

Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)

American journal of clinical dermatology, 2022-05, Vol.23 (3), p.365-383

2022

Volltextzugriff (PDF)

Controlled, one-pot synthesis of recyclable poly(1,3-diene)-polyester block copolymers, catalyzed by yttrium β-diketiminate complexes

Chemical science (Cambridge), 2022-08, Vol.13 (33), p.9515-9524

2022

Volltextzugriff (PDF)

Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment

The New England journal of medicine, 2017-10, Vol.377 (15), p.1448-1455

2017

Volltextzugriff (PDF)

Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered With Human Immunodeficiency Virus Antiretrovirals

The Journal of infectious diseases, 2020-01, Vol.221 (2), p.223-231

2020

Volltextzugriff (PDF)

Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical Development

Clinical pharmacology and therapeutics, 2024-03, Vol.115 (3), p.422-439

2024

Volltextzugriff (PDF)

BL-1023 improves behavior and neuronal survival in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice

Neuroscience, 2011-04, Vol.180, p.293-304

2011

Volltextzugriff (PDF)

Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6–11 Years of Age with Severe Atopic Dermatitis

Dermatology and therapy, 2023-11, Vol.13 (11), p.2697-2719

2023

Volltextzugriff (PDF)

Inside the prison black box: toward a life course importation model of inmate behavior

International journal of offender therapy and comparative criminology, 2011-12, Vol.55 (8), p.1186-1207

2011

Volltextzugriff (PDF)

Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection

Clinical gastroenterology and hepatology, 2019-02, Vol.17 (3), p.527-535.e6

2019

Volltextzugriff (PDF)

Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment

European journal of clinical pharmacology, 2019-02, Vol.75 (2), p.217-226

2019

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate‐to‐severe atopic dermatitis: Results from two terminated phase II trials

Clinical and translational science, 2024-08, Vol.17 (8), p.e13874-n/a

2024

Volltextzugriff (PDF)

Drug‐Drug Interactions of Tacrolimus or Cyclosporine With Glecaprevir and Pibrentasvir in Healthy Subjects

Clinical pharmacology in drug development, 2019-08, Vol.8 (6), p.779-789

2019

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Experimental demonstration of a receiver beating the standard quantum limit for multiple nonorthogonal state discrimination

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

Demonstration of nonorthogonal multi-state discrimination below the standard quantum limit

Beating the standard quantum limit for nonorthogonal multi-state discrimination

A Phase II Trial of Lutikizumab, an Anti–Interleukin‐1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis

Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study

Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis

A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy

A Dimensional Analysis of Caregiver Burden among Spouses and Adult Children

Safety, tolerability, and pharmacodynamics of an anti-interleukin-1α/β dual variable domain immunoglobulin in patients with osteoarthritis of the knee: a randomized phase 1 study

Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial

Selective VIP Receptor Agonists Facilitate Immune Transformation for Dopaminergic Neuroprotection in MPTP-Intoxicated Mice

Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir

Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)

Controlled, one-pot synthesis of recyclable poly(1,3-diene)-polyester block copolymers, catalyzed by yttrium β-diketiminate complexes

Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment

Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered With Human Immunodeficiency Virus Antiretrovirals

Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical Development

BL-1023 improves behavior and neuronal survival in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice

Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6–11 Years of Age with Severe Atopic Dermatitis

Inside the prison black box: toward a life course importation model of inmate behavior

Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection

Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment

Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate‐to‐severe atopic dermatitis: Results from two terminated phase II trials

Drug‐Drug Interactions of Tacrolimus or Cyclosporine With Glecaprevir and Pibrentasvir in Healthy Subjects

Suchergebnisse filtern